STEMI Management: Primary PCI, Fibrinolysis, DAPT Selection, and Door-to-Balloon Quality Metrics
Evidence-based STEMI care from prehospital ECG and triage through primary PCI, antithrombotic selection, complete revascularization, mechanical complication recognition, and post-MI guideline-directed medical therapy - aligned with 2023 ESC and 2025 ACC/AHA STEMI guidelines.
Executive Summary
STEMI represents complete thrombotic occlusion of an epicardial coronary artery requiring emergent reperfusion. Time is myocardium - every 30-minute delay in reperfusion increases 1-year mortality by approximately 7.5%. Primary PCI within 90 minutes door-to-balloon at PCI-capable centers (or 120 minutes FMC-to-device at non-PCI centers requiring transfer) is the dominant strategy. Fibrinolysis remains essential when timely PCI is unavailable - administered within 30 minutes door-to-needle followed by routine angiography 3-24 hours later (pharmaco-invasive strategy). Antithrombotic regimen: aspirin 325 mg load + ticagrelor 180 mg load (or prasugrel 60 mg if low-bleeding-risk PCI candidate, or clopidogrel 600 mg if fibrinolysis or contraindications) + heparin or bivalirudin during PCI. Radial access reduces bleeding and mortality (MATRIX, RIVAL trials) - now Class I. Complete revascularization of significant non-culprit lesions during index admission or staged within 4-6 weeks improves outcomes (COMPLETE, FULL REVASC) - except in cardiogenic shock (CULPRIT-SHOCK). Post-MI GDMT pillars include 12-month DAPT, high-intensity statin (LDL <55), beta-blocker, ACEi/ARB (mandatory if EF <40%), aldosterone antagonist (EF <40% with HF/DM), SGLT2 inhibitor, and cardiac rehab.
1. Pathophysiology and ECG Diagnosis
Atherothrombosis: The Vulnerable Plaque Cascade
STEMI results from acute thrombotic occlusion of an epicardial coronary artery. The proximate event is plaque rupture (60-70% of cases) or plaque erosion (30-40%) of a previously non-flow-limiting atheroma. The vulnerable plaque is characterized by a thin fibrous cap (less than 65 micrometers), large lipid-rich necrotic core, infiltration by activated macrophages and T cells, and surface inflammation. Triggers include adrenergic surges (morning, exercise, emotional stress), inflammation (sepsis, surgery), and prothrombotic states.
Plaque rupture exposes subendothelial collagen and tissue factor, triggering platelet adhesion via GPIb-vWF and GPVI-collagen, platelet activation through thromboxane A2 and ADP release, GPIIb/IIIa-mediated platelet aggregation, and tissue factor-driven thrombin generation. The resulting platelet-fibrin thrombus completely occludes the vessel, producing transmural ischemia. Without reperfusion, irreversible myocyte necrosis begins within 20-30 minutes (subendocardial wavefront) and progresses outward over 6 hours, after which most salvageable myocardium is lost.
Reperfusion within 90-120 minutes salvages substantial myocardium. Beyond 12 hours, mechanical reperfusion offers diminishing benefit unless symptoms persist or hemodynamic instability is present. The "open artery hypothesis" - late reperfusion offers structural and electrical benefit beyond myocardial salvage - has been largely refuted (OAT trial). Right ventricular infarction (40% of inferior STEMI) involves the proximal RCA before the RV branch and is recognized by V4R ST elevation - treated with volume loading, avoidance of nitrates/diuretics, and emergent reperfusion.
STEMI ECG Diagnostic Criteria
Standard criteria (4th Universal Definition of MI, 2018):
- New ST elevation at the J-point in 2 contiguous leads
- ≥1 mm in all leads except V2-V3
- V2-V3 thresholds: ≥2 mm men age ≥40, ≥2.5 mm men <40, ≥1.5 mm women regardless of age
- Reciprocal ST depression in opposing leads supports the diagnosis
| Lead Distribution | Coronary Territory | Reciprocal Changes | Clinical Notes |
|---|---|---|---|
| V1-V4 (anterior) | LAD - proximal or mid | II, III, aVF | Largest infarct; high mortality; LV failure risk |
| V1-V6 + I, aVL (extensive anterior) | Proximal LAD before D1 | II, III, aVF | Anterior + lateral; very high mortality; cardiogenic shock |
| I, aVL, V5-V6 (lateral) | LCx or D1 of LAD | II, III, aVF | Often missed; check posterior leads |
| II, III, aVF (inferior) | RCA (80%) or LCx (20%) | I, aVL | Check V4R for RV infarct; hypotension with nitrates |
| V4R ST elevation ≥1 mm (RV infarct) | Proximal RCA | — | Volume loading; avoid nitrates/diuretics |
| ST depression V1-V3 with tall R (posterior) | LCx or RCA (PDA) | V7-V9 ST elevation ≥0.5 mm | Often missed - obtain posterior leads |
| Sinus tachycardia + diffuse ST↑ + aVR ST elevation | Left main coronary artery | Diffuse ST depression | Cardiogenic shock; emergent PCI |
STEMI Equivalents (Treat as STEMI)
- New LBBB with Sgarbossa criteria: concordant ST elevation ≥1 mm (5 points), concordant ST depression ≥1 mm V1-V3 (3 points), discordant ST elevation ≥5 mm or Smith modification (excessive discordance ratio >0.25) - score ≥3 highly specific for acute MI.
- Posterior STEMI: ST depression ≥0.5 mm in V1-V3 with prominent R waves; confirm with posterior leads V7-V9 (≥0.5 mm ST elevation diagnostic).
- De Winter T waves: upsloping ST depression with tall symmetric T waves V1-V6 - proximal LAD occlusion equivalent.
- aVR ST elevation ≥1 mm with diffuse ST depression: left main or proximal LAD occlusion.
- Hyperacute T waves: tall, broad-based, asymmetric T waves - earliest STEMI sign, may precede ST elevation.
- Wellens syndrome: deep T-wave inversions or biphasic T waves V2-V3 in pain-free state - critical proximal LAD stenosis, high MI risk.
⚠️ Always obtain serial 15-lead ECGs in suspected ACS
Initial ECG misses 30-40% of STEMI on first capture. Repeat at 10-15 minutes if symptoms persist. Add V7-V9 (posterior) and V3R-V4R (right-sided) leads for inferior or undifferentiated chest pain. Activate the cath lab on first diagnostic ECG - do not wait for troponin.
2. Risk Stratification and Initial Assessment
TIMI Risk Score for STEMI
The TIMI Risk Score for STEMI (8 variables, max 14 points) predicts 30-day mortality:
- Age 65-74: 2 points; Age ≥75: 3 points
- Diabetes, HTN, or angina history: 1 point
- SBP <100 mmHg: 3 points
- HR >100 bpm: 2 points
- Killip class II-IV: 2 points
- Weight <67 kg: 1 point
- Anterior STEMI or LBBB: 1 point
- Time to treatment >4 hours: 1 point
Mortality stratification: 0 points = 0.8%, 5 points = 12%, 8+ points = 36% at 30 days. High TIMI score (≥5) flags need for ICU admission, mechanical support readiness, and aggressive revascularization.
Killip Classification (Hemodynamic Status)
| Class | Clinical Findings | 30-day Mortality | Implication |
|---|---|---|---|
| I | No HF signs | ~6% | Standard care |
| II | S3 gallop, basal rales, JVD | ~17% | Diuretics, ACEi early |
| III | Pulmonary edema | ~38% | NIV/intubation, IV diuretics, vasodilators |
| IV | Cardiogenic shock (SBP <90, hypoperfusion) | ~80% (without MCS) | Inotropes, MCS (Impella, IABP, VA-ECMO), urgent PCI of culprit only |
Initial ED Management Bundle (First 30 Minutes)
- Recognize STEMI on prehospital or door ECG within 10 minutes of arrival.
- Activate cath lab immediately on diagnostic ECG (parallel processing - do not wait for labs).
- IV access × 2 (large-bore peripheral; femoral central if shock).
- Cardiac monitor and defibrillator at bedside - VF/pulseless VT highest in first hour.
- Oxygen only if SaO2 <90% (DETO2X-AMI: routine O2 not beneficial and possibly harmful).
- Aspirin 325 mg PO chewed immediately (or 162 mg).
- P2Y12 inhibitor: ticagrelor 180 mg PO load (preferred) OR prasugrel 60 mg (if PCI candidate, no contraindications) OR clopidogrel 600 mg.
- Anticoagulation: unfractionated heparin 60 U/kg IV bolus (max 4000 U) → 12 U/kg/hr infusion (max 1000 U/hr) targeting aPTT 50-70 seconds; OR enoxaparin 30 mg IV bolus + 1 mg/kg SC; OR bivalirudin 0.75 mg/kg IV bolus then 1.75 mg/kg/hr.
- Pain control: sublingual or IV nitroglycerin (avoid in inferior/RV MI, hypotension, recent PDE5 inhibitor); morphine 2-4 mg IV (use sparingly - delays oral antiplatelet absorption per IMPRESSION trial).
- Beta-blocker: oral metoprolol 25 mg if hemodynamically stable (avoid IV beta-blocker in shock per COMMIT trial).
- Statin: high-intensity (atorvastatin 80 mg or rosuvastatin 40 mg) on arrival.
- Notify family, prepare for transport to cath lab.
🚨 Avoid in STEMI
(1) NSAIDs other than aspirin - increase mortality, reinfarction, hypertension. (2) Routine high-flow oxygen if SaO2 ≥90% - increases coronary vasoconstriction. (3) IV beta-blockers in unstable hemodynamics or signs of HF (Killip ≥III) - associated with cardiogenic shock per COMMIT. (4) Nitrates in inferior STEMI with RV involvement - profound hypotension. (5) Routine GPIIb/IIIa inhibitors with bivalirudin - adds bleeding without ischemic benefit. (6) Empiric thrombolysis without confirmed STEMI ECG.
3. Primary PCI vs Fibrinolysis Decision
Reperfusion Timing Algorithm
Fibrinolytic Selection and Dosing
| Agent | Dose | Notes |
|---|---|---|
| Tenecteplase (TNK-tPA) | Single IV bolus 30-50 mg (weight-based: <60 kg = 30 mg, 60-69 = 35, 70-79 = 40, 80-89 = 45, ≥90 = 50; HALF-DOSE if age ≥75) | Most fibrin-specific; preferred in modern practice; STREAM half-dose elderly trial |
| Alteplase (rt-PA) | 15 mg IV bolus → 0.75 mg/kg over 30 min (max 50) → 0.5 mg/kg over 60 min (max 35); total ≤100 mg | Original lytic; complex dosing |
| Reteplase (r-PA) | 10 U IV bolus, repeat at 30 min | Less fibrin-specific than TNK |
| Streptokinase (rare) | 1.5 million U IV over 30-60 min | Antigenic, lower efficacy; mostly historical or LMIC use |
Adjunctive antithrombotics with fibrinolysis:
- Aspirin 325 mg load → 81 mg daily lifelong
- Clopidogrel 300 mg load (75 mg if age >75 due to bleeding risk) → 75 mg daily for 14 days minimum, then per stent
- Enoxaparin: 30 mg IV bolus + 1 mg/kg SC q12h (no IV bolus and 0.75 mg/kg q12h if age ≥75; 1 mg/kg q24h if CrCl <30); duration up to hospital discharge or 8 days
- Alternative: UFH 60 U/kg IV bolus (max 4000) + 12 U/kg/hr infusion targeting aPTT 50-70 seconds for 48 hours
Absolute and Relative Contraindications to Fibrinolysis
| Absolute | Relative |
|---|---|
|
|
Failed Fibrinolysis - Rescue PCI
Assess reperfusion at 60-90 minutes post-fibrinolysis. Indicators of failure: less than 50% ST resolution in the worst lead, persistent chest pain, hemodynamic or electrical instability. Rescue PCI improves outcomes (REACT trial) - emergent transfer for catheterization. Successful fibrinolysis still warrants routine angiography 3-24 hours later (CARESS-in-AMI, TRANSFER-AMI) - the pharmaco-invasive strategy.
4. Antithrombotic Therapy and DAPT Selection
P2Y12 Inhibitor Comparison
| Drug | Loading / Maintenance | Onset | Reversal | Trial | Notes |
|---|---|---|---|---|---|
| Ticagrelor (Brilinta) | 180 mg load → 90 mg BID | 30 min | None (12h half-life) | PLATO | Preferred 1st-line ESC 2023; reversible inhibition; dyspnea (15%); avoid with strong CYP3A4 inhibitors; lifelong aspirin 81 mg co-administered |
| Prasugrel (Effient) | 60 mg load → 10 mg daily (5 mg if <60 kg or age ≥75) | 30 min | None | TRITON-TIMI 38, ISAR-REACT 5 | Superior to ticagrelor for PCI (ISAR-REACT 5); contraindicated with prior stroke/TIA, age ≥75 unless DM/prior MI |
| Clopidogrel (Plavix) | 600 mg load → 75 mg daily (300 mg load if age >75 with fibrinolysis) | 2-6 h | None | CLARITY, COMMIT | Use if ticagrelor/prasugrel contraindicated; CYP2C19 *2/*3 reduced metabolism (genotyping per TAILOR-PCI); standard with fibrinolysis |
| Cangrelor | 30 mcg/kg IV bolus + 4 mcg/kg/min infusion | 2 min | ~60 min | CHAMPION-PHOENIX | IV reversible; useful when oral antiplatelet not feasible (intubated, vomiting); transition to oral within 30 min of stop |
Anticoagulation During PCI
- Unfractionated heparin: 70-100 U/kg IV bolus (50-70 U/kg if GPIIb/IIIa inhibitor planned), target ACT 250-300 sec (200-250 with GPIIb/IIIa). Most commonly used; reversible with protamine.
- Bivalirudin: 0.75 mg/kg IV bolus + 1.75 mg/kg/hr infusion. Equivalent ischemic outcomes vs UFH with less bleeding (HORIZONS-AMI, MATRIX). Preferred for patients at high bleeding risk; expensive.
- Enoxaparin: 0.5 mg/kg IV bolus during PCI for patients pretreated with SC enoxaparin (ATOLL trial supportive but not definitive).
- Fondaparinux: NOT for primary PCI (catheter thrombus risk per OASIS-6) - only with conservative or fibrinolytic strategy.
GPIIb/IIIa Inhibitors
Routine upstream GPIIb/IIIa is no longer recommended (BRAVE-3, FINESSE). Reserved for "bailout" use during PCI for high thrombus burden, slow flow/no-reflow, or thrombotic complications. Agents: abciximab 0.25 mg/kg bolus + 0.125 mcg/kg/min × 12h; eptifibatide 180 mcg/kg bolus × 2 + 2 mcg/kg/min × 12h; tirofiban 25 mcg/kg over 3 min + 0.15 mcg/kg/min × 12h. Major bleeding ×2 vs placebo - balance against ischemic benefit case-by-case.
DAPT Duration and De-escalation Strategies
Standard: 12 months DAPT after drug-eluting stent for STEMI. Recent trials support flexibility:
- High bleeding risk: abbreviated 1-3 months DAPT then aspirin or P2Y12 monotherapy (MASTER DAPT, STOPDAPT-2 ACS) - maintains ischemic protection with less bleeding.
- Low bleeding risk + high ischemic risk: extend DAPT beyond 12 months or use ticagrelor 60 mg BID monotherapy (PEGASUS-TIMI 54) - 1-3 years of extended therapy reduces ischemic events.
- De-escalation: switch from ticagrelor/prasugrel to clopidogrel after 1-3 months in patients with bleeding events or platelet function-guided strategy (TROPICAL-ACS).
- Triple therapy with concomitant AF: 1 week DAPT + DOAC then DOAC + clopidogrel for 6-12 months then DOAC monotherapy (AUGUSTUS, ENTRUST-AF-PCI, RE-DUAL PCI) - minimizes bleeding while preserving ischemic protection.
💎 Pearl: ISAR-REACT 5 changed the prasugrel-vs-ticagrelor calculus
For PCI-treated ACS patients without prasugrel contraindications (no prior stroke/TIA, age <75, weight ≥60 kg), ISAR-REACT 5 (2019) showed prasugrel reduced the composite of death/MI/stroke vs ticagrelor (6.9% vs 9.3%, HR 0.83) without increased major bleeding. Prasugrel is now preferred in PCI candidates meeting criteria. Ticagrelor remains first-line when angiographic anatomy is unknown (medical management or pre-cath), prior stroke/TIA, or in fibrinolysis - and offers lifestyle simplicity (BID dosing).
⚠️ Pitfall: Mixing aspirin doses with ticagrelor
PLATO subgroup analysis showed reduced ticagrelor benefit with aspirin doses >100 mg/day (US site effect, possibly attributable to higher aspirin dosing). Always pair ticagrelor with aspirin 75-100 mg/day - NOT 325 mg/day for chronic maintenance. Loading dose aspirin 325 mg one-time is fine; maintenance must be low-dose. This is one of the most common prescribing errors in post-MI care.
5. PCI Strategy, Complete Revascularization, and Cardiogenic Shock
Radial vs Femoral Access
Radial access is now Class I (ESC 2023, ACC/AHA 2025). MATRIX (8404 ACS patients) and RIVAL (7021 ACS) showed radial access reduces major bleeding by 50% and mortality by 30% vs femoral in STEMI. Operator volume matters - centers and operators with lower radial volumes show attenuated benefit. Modern dual access strategies: radial primary, femoral backup for hemodynamic support (Impella, IABP, ECMO cannulation).
Stent Selection
- Drug-eluting stents (DES) preferred over bare-metal stents for all STEMI - reduced restenosis with equivalent stent thrombosis rates in modern second-generation DES (everolimus, zotarolimus).
- Bioresorbable scaffolds: initial enthusiasm tempered by ABSORB III long-term data showing increased late thrombosis - largely abandoned.
- Drug-coated balloons (DCB): useful for in-stent restenosis, small vessels (≤2.5 mm), bifurcation side branches, and high bleeding risk - allows shorter DAPT.
- Aspiration thrombectomy: NOT routine (TASTE, TOTAL trials neutral; possible stroke signal). Reserved for high thrombus burden when adjunct techniques (no-reflow management) needed.
Complete Revascularization Strategy
For multi-vessel disease in stable STEMI patients (50-60% of STEMI):
- COMPLETE trial (2019): staged PCI of significant non-culprit lesions (within 45 days) reduced CV death/MI by 26% vs culprit-only.
- FULL REVASC (2024): FFR-guided complete revascularization at index admission noninferior to staged.
- FIRE (2023): in older adults (≥75) with multivessel STEMI, complete revascularization superior to culprit-only (15.7% vs 20.6% MACE at 1 year).
- Strategy: Complete during index admission (preferred for stable patients) OR staged within 4-6 weeks. Use FFR/iFR or angiographic stenosis ≥70% to identify hemodynamically significant non-culprit lesions.
🚨 EXCEPTION: Cardiogenic shock - culprit-only PCI
CULPRIT-SHOCK trial (2017): in STEMI complicated by cardiogenic shock, culprit-only PCI at index procedure REDUCED 30-day mortality vs immediate multi-vessel PCI (45.9% vs 51.5%). Mechanism: contrast load, prolonged procedure time, and additional ischemic burden in already-stressed patient. Stage non-culprit revascularization after stabilization. This is the key STEMI guideline exception to remember.
Cardiogenic Shock Management
Defined as SBP <90 mmHg for ≥30 min (or vasopressors required to maintain SBP ≥90), with hypoperfusion (cool extremities, oliguria, altered mental status, lactate >2). Mortality 30-50% with current therapy.
Mechanical Circulatory Support Hierarchy
| Device | Hemodynamic Effect | Indication | Trial Evidence |
|---|---|---|---|
| IABP | Modest CO augmentation (0.5 L/min); afterload reduction | Bridge to recovery or definitive therapy; no longer Class I in shock | IABP-SHOCK II (negative) |
| Impella CP/5.5 | 2.5-5.5 L/min unload of LV; direct ventricular unloading | Pre-PCI insertion preferred; STEMI shock; high-risk PCI | DanGer Shock (2024 - positive!) |
| VA-ECMO | Full cardiopulmonary support; complete cardiac unloading possible with LV vent | Refractory shock; biventricular failure; hypoxemic | EURO-ECMO-SHOCK (mixed) |
| TandemHeart | Trans-septal LA→femoral artery 4 L/min | RV failure or severe biventricular shock | Limited RCT data |
DanGer Shock (2024): Impella CP plus standard care vs standard care alone in STEMI cardiogenic shock - 6-month mortality 45.8% vs 58.5% (HR 0.74). First positive trial of mechanical support in cardiogenic shock. Adopted into 2024 ESC heart failure focused update as a tool to consider in selected patients. Vascular complications (severe bleeding, limb ischemia, hemolysis) higher with Impella - careful patient selection required.
Vasoactive Strategy in Cardiogenic Shock
- Norepinephrine first-line vasopressor (lower mortality vs epinephrine per OptimaCC trial)
- Dobutamine 2.5-10 mcg/kg/min for inotropic support in normotensive patients with low CO
- Milrinone 0.25-0.75 mcg/kg/min for inotropy without beta-receptor stimulation; useful in beta-blocker-treated patients but causes hypotension
- Avoid epinephrine as primary vasopressor (more arrhythmia, lactic acidosis)
Practice Insights — Bedside Notes on STEMI Primary PCI
(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)Across published practice patterns, the two patterns experienced clinicians keep refining are recognizing "STEMI without ST elevation" patterns that deserve emergent cath despite the textbook ECG criteria being absent, and committing to pharmaco-invasive strategy when transfer for primary PCI cannot meet the 120-minute window.
The "STEMI Without ST Elevation" Patterns That Need Cath
Several ECG patterns are functionally equivalent to STEMI but do not meet the classical ST-elevation criteria, and seasoned clinicians treat all of them with emergent cath activation in practice. Posterior STEMI: tall R waves and ST depression in V1–V3 mirror the unseen posterior ST elevation; confirm with posterior leads V7–V9. De Winter T waves: upsloping ST depression with tall symmetric T waves in precordial leads = proximal LAD occlusion equivalent. Wellens syndrome: deeply inverted or biphasic T waves in V2–V3 in a pain-free patient — critical LAD lesion that will infarct without intervention. Isolated aVR ST elevation: left main or triple-vessel disease. Modified Sgarbossa criteria in LBBB: concordant ST elevation, concordant ST depression, or discordant ST elevation >1 mm with ST/S ratio. These get the same activation as a textbook STEMI.
FMC-to-Balloon Time Anchors the Decision
The first medical contact (FMC) to balloon time goal is ≤90 minutes at a PCI center and ≤120 minutes if transfer is required. In practice the FMC-to-balloon clock starts when EMS arrives or the patient registers in a non-PCI ED; the cath lab activation happens off the field ECG with EMS, not after re-confirmation at the ED. Pre-arrival aspirin 162–325 mg chewed, ticagrelor 180 mg loaded, and unfractionated heparin 60 U/kg IV bolus are given by EMS or the referring ED so the patient arrives at the table loaded. If projected FMC-to-balloon exceeds 120 minutes, pharmaco-invasive strategy is the answer, not heroic transport.
Pharmaco-Invasive Strategy When Transfer Delay >120 Min
For patients presenting to non-PCI centers where transfer for primary PCI will exceed 120 minutes from FMC, the pharmaco-invasive strategy beats prolonged transfer. Tenecteplase 30–50 mg IV single bolus (weight-adjusted) plus aspirin, clopidogrel 300 mg load (NOT ticagrelor or prasugrel with fibrinolysis), and enoxaparin 30 mg IV bolus + 1 mg/kg SC q12h. Transfer to a PCI center is initiated immediately after fibrinolytic administration, with cath performed at 2–24 hours regardless of clinical response. Rescue PCI immediately if no clinical reperfusion at 60–90 minutes post-fibrinolytic. The pharmaco-invasive approach gives most patients reperfusion within the window when geography prevents primary PCI.
Inferior STEMI With V4R Elevation = RV Infarct — No Nitrates
Inferior STEMI patients (ST elevation in II, III, aVF) need V4R checked routinely because right ventricular infarction in the setting of inferior STEMI is preload-dependent and acutely sensitive to nitroglycerin. RV STEMI clues: lead II ST elevation greater than lead III, V4R ST elevation greater than 1 mm, hypotension on small nitro dose. In practice inferior STEMI patients get a 12-lead with right-sided V4R added before any nitroglycerin is dosed. If RV infarction is present, IV fluids are first-line (250–500 mL boluses titrated to BP) and nitroglycerin is contraindicated. Experienced practitioners have personally watched outside hospitals give SL nitro to RV STEMI patients and induce profound hypotension that took 30 minutes of crystalloid plus norepinephrine to reverse.
Illustrative Scenario — Pre-Hospital Activation, Door-to-Balloon 45 Minutes
(Composite teaching scenario assembled from published patterns; not an individual patient.)A man in his late 50s, smoker with hypertension, developed crushing substernal chest pain at home for 40 minutes before calling EMS. Pre-hospital 12-lead ECG transmitted to the receiving cath lab showed 4 mm ST elevation in V1–V4 with reciprocal depression in II, III, aVF — anterior STEMI from likely proximal LAD occlusion. The cath lab activation went out from EMS directly, bypassing the ED. EMS gave aspirin 325 mg chewed, ticagrelor 180 mg PO load, unfractionated heparin 60 U/kg IV bolus en route. The patient bypassed ED triage and went straight to the cath lab on arrival. First medical contact to balloon inflation time was 45 minutes; the culprit was a proximal LAD 100% thrombotic occlusion, treated with aspiration thrombectomy followed by drug-eluting stent. Door-to-balloon (registration to inflation) was 28 minutes; pre-discharge LVEF 45% with anterior wall hypokinesis. He was discharged on day 4 on aspirin 81, ticagrelor 90 BID, atorvastatin 80, carvedilol uptitrated, lisinopril 10, dapagliflozin 10, with cardiac rehab in week 1.
Takeaway: pre-hospital ECG transmission with EMS-direct cath lab activation is the highest-yield STEMI system intervention available. Door-to-balloon is the wrong metric; FMC-to-balloon is what saves myocardium.
Protocol Adjustments Experienced Clinicians Use Beyond the Standard Guideline
- Pre-hospital ECG with EMS-direct cath lab activation — bypass ED triage when STEMI is clear on field ECG. Pre-arrival aspirin + ticagrelor + UFH so the patient arrives loaded for the table.
- STEMI-equivalent ECG patterns activate emergent cath — posterior STEMI (V1–V3 mirror), de Winter T waves, Wellens, aVR elevation, modified Sgarbossa in LBBB. Don't wait for textbook ST elevation.
- Pharmaco-invasive if projected FMC-to-balloon >120 min — TNK weight-adjusted single bolus + clopidogrel 300 mg load + enoxaparin. Transfer for PCI at 2–24 h regardless of clinical response.
- Right-sided V4R lead on every inferior STEMI before any nitro — RV infarction is preload-dependent; nitroglycerin is contraindicated. IV fluids 250–500 mL boluses titrated to BP.
6. Mechanical Complications, Post-MI GDMT, and FAQ
Mechanical Complications (3-7 Days Post-MI)
Era of routine reperfusion has reduced incidence of mechanical complications from 5-10% to under 2%, but mortality remains high without prompt recognition.
| Complication | Timing | Clinical Picture | Diagnosis | Management |
|---|---|---|---|---|
| Free wall rupture | Day 3-7 | Sudden hemodynamic collapse, PEA arrest, tamponade | Bedside echo: pericardial effusion, tamponade | Emergent surgery; pericardiocentesis temporizing; mortality >90% |
| Ventricular septal defect (VSD) | Day 3-5 (anterior MI - apical VSD; inferior MI - basal VSD) | New harsh holosystolic murmur, biventricular failure | Echo with color Doppler; RV oxygen step-up on PA cath | IABP/Impella bridge; surgical closure (delayed if possible) or percutaneous device |
| Papillary muscle rupture | Day 3-5; usually inferior MI (posteromedial PM has single blood supply) | Acute severe MR, flash pulmonary edema, hypotension, shock | Echo: flail leaflet, severe MR jet | Emergent valve repair/replacement; IABP bridge; mortality 50% even with surgery |
| LV pseudoaneurysm | Days to weeks | Contained rupture - thrombus seals defect | Echo: narrow neck, broad sac | Urgent surgical repair (high rupture risk) |
| True LV aneurysm | Weeks to months | Persistent ST elevation; HF symptoms; ventricular arrhythmia | Echo or cardiac MRI | Anticoagulation if thrombus; surgery for HF/arrhythmia refractory cases |
| LV thrombus | Days to weeks (anterior MI, EF <30%) | Often asymptomatic; embolic stroke | Echo with contrast or cardiac MRI (MRI more sensitive) | Warfarin 3-6 months (target INR 2-3); DOAC growing evidence |
| Dressler syndrome | 2-10 weeks post-MI | Pleuropericarditis, fever, pericardial effusion | Clinical + echo; ECG diffuse PR depression | NSAIDs (avoid in early post-MI), colchicine 0.6 mg BID × 3 months; corticosteroids if refractory |
| Post-infarction ventricular arrhythmia | Hours to days | Sustained VT/VF | Telemetry, ECG | Beta-blocker, amiodarone, ICD evaluation if EF ≤35% at 40 days post-MI per MADIT-II |
Post-MI GDMT - Five Pillars
| Pillar | Drug Class / Examples | Indication | Target |
|---|---|---|---|
| 1. Antiplatelet | Aspirin 81 mg + ticagrelor 90 mg BID (or prasugrel 10 mg, or clopidogrel 75 mg) | All post-MI | DAPT 12 months → aspirin lifelong |
| 2. Lipid lowering | High-intensity statin (atorvastatin 80 mg, rosuvastatin 20-40 mg); add ezetimibe 10 mg, PCSK9 inhibitor (alirocumab/evolocumab) if needed | All post-MI | LDL <55 mg/dL (≥50% reduction from baseline) |
| 3. Beta-blocker | Metoprolol succinate 25-200 mg, carvedilol 6.25-25 mg BID, bisoprolol 1.25-10 mg | All post-MI; especially EF <40% (CAPRICORN) | HR 60-70 bpm; titrate to max tolerated |
| 4. RAAS inhibition | ACEi (lisinopril, ramipril, enalapril) or ARB (valsartan, candesartan); ARNI (sacubitril-valsartan) if EF reduced | EF <40%, anterior MI, DM, HTN, CKD | Max tolerated dose; check Cr/K+ at 1-2 weeks |
| 5. Aldosterone antagonist | Eplerenone 25-50 mg or spironolactone 25 mg | EF <40% with HF symptoms or DM (EPHESUS) | K+ <5.0; eGFR >30 |
| 6. (NEW) SGLT2 inhibitor | Dapagliflozin 10 mg, empagliflozin 10 mg | EF <40%, DM, CKD; emerging post-MI evidence (DAPA-MI, EMPACT-MI) | Once daily regardless of glucose |
| 7. Cardiac rehabilitation | Supervised exercise + risk factor modification + education | All post-MI | 36 sessions over 12 weeks |
Quality Metrics and Performance Measures
- Door-to-balloon (D2B): ≤90 minutes for primary PCI (≥75% of cases) - CMS quality measure
- FMC-to-device: ≤120 minutes for transferred patients
- Door-to-needle (D2N): ≤30 minutes for fibrinolysis
- Aspirin within 24 hours: ≥98% of STEMI patients
- Beta-blocker at discharge: ≥95% (excluding contraindications)
- Statin at discharge: ≥95%
- ACEi/ARB at discharge if EF ≤40%: ≥95%
- Cardiac rehab referral: ≥85%
Discharge Checklist
📋 Pre-discharge bundle
Medications: aspirin 81 mg + P2Y12 + high-intensity statin + beta-blocker + ACEi/ARB if indicated + aldosterone antagonist if EF <40% with HF/DM + SGLT2i if indicated. Imaging: pre-discharge TTE for EF, regional wall motion, valvular complications, LV thrombus. Risk modification: smoking cessation counseling + pharmacotherapy (varenicline, NRT), influenza/pneumococcal vaccination, glycemic control, BP <130/80, weight management. Activity: cardiac rehab referral; gradual return to activity; sexual activity safe at 1 week if asymptomatic. Follow-up: cardiology at 2 weeks (clinical assessment, lipid recheck at 4-6 weeks, ECG), primary care, EF reassessment at 40 days for ICD eligibility (if EF ≤35%).
When to Refer to Advanced Heart Failure
- Refractory cardiogenic shock requiring durable MCS or transplant evaluation
- Persistent EF ≤35% despite 3 months of GDMT - ICD ± CRT-D candidacy
- Recurrent decompensated HF hospitalizations
- Refractory ventricular arrhythmias
- Mechanical complications requiring complex surgical repair
Frequently Asked Questions
- Mitral Regurgitation: Primary vs Secondary, Imaging, and TEER Indications
- Takotsubo Cardiomyopathy: Diagnosis and Management
- Complete Heart Block: Diagnosis and Management
- Tricuspid Regurgitation: Diagnosis and Management
- Syncope: Evaluation, Risk Stratification, and Management
- ST-Elevation Myocardial Infarction — Emergency Diagnosis and Reperfusion Therapy